The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: Findings from the Isfahan Healthy Heart Program, 2001-2007

Archives of Medical Science

Volumn 8, Issue 6, 2012, Pages 1009-1017

  Gharipour, Mojgan ^a   Kelishadi, Roya ^a   Khosravi, Alireza ^b   Shirani, Shahin ^b   Masjedi, Mohsen ^c   Sarrafzadegan, Nizal ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Community trial; Iran; Metabolic syndrome; Pharmacological treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN ZINC SUSPENSION; METFORMIN; NICOTINIC ACID; PHENFORMIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HERBAL MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PREVALENCE; URBAN AREA;

EID: 84873196840     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.32407     Document Type: Article

References (30)

1. Tankova TI, Chakarova NV, Dakovska LN, Kalinov KB, Atanassova IA. Assessment of the risk for metabolic syndrome in prediabetes and newly-diagnosed type 2 diabetes. J Diabetol 2010;2:1-5.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2000;104:2855-64. (Pubitemid 33126663)
3. Lopes N, Zanini AC, Casella-Filho A, Chagas AC. Metabolic syndrome patient compliance with drug treatment. Clinics (Sao Paulo) 2008;63:573-80.
4. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52. (Pubitemid 41532612)
5. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India 2006;54:797-810. (Pubitemid 44563740)
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
7. Bertrais S, Beyeme-Ondoua JP, Czernichow S, Galan P, Hercberg S, Oppert JM. Sedentary behaviors, physical activity, and metabolic syndrome in middle-aged French subjects. Obes Res 2005;13:936-44.
8. Baghaei A, Sarrafzadegan N, Rabiei K, et al. How effective are strategies for non-communicable disease prevention and control in a high risk population in a developing country? Isfahan Healthy Heart Programme. Arch Med Sci 2010;6:24-31.
9. Grundy SM. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 1999;100:988-98. (Pubitemid 29407181)
10. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension 2000;35:858-63. (Pubitemid 30303940)
11. Sarraf-Zadegan N, Sadri G, Malek Afzali H, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol 2003;58:309-20. (Pubitemid 36961867)
12. Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, et al. Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull World Health Organ 2009;87:39-50.
13. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S. Isfahan Healthy Heart Program: evaluation of comprehensive, communitybased interventions for non-communicable disease. Prev Control J 2006;2:73-84. (Pubitemid 44933115)
14. Sarrafzadegan N, Kelishadi R, Baghaei A, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. Int J Cardiol 2008;131:90-6.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9. (Pubitemid 34251969)
16. Agrawal V, Shah A, Rice C, Franklin BA, McCullough PA. Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol 2009;5:520-8.
17. Expert Bianchi C, Penno G, Romero F, Del Prato S, Mic-Coli R. Treating the metabolic syndrome. Rev Cardiovasc Ther 2007;5:491-506. (Pubitemid 46812959)
18. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009;32:1092-7.
19. Gharipour M, Kelishadi R, Toghianfar N, et al. Pharmacological treatment of cardiovascular risk factors in individuals with metabolic syndrome: findings from Isfahan Healthy Heart Program. African J Pharm Pharmacol 2011;5:311-6.
20. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. JAPI 2006;54:797-810. (Pubitemid 44563740)
21. Fordis M, King JE, Ballantyne CM, et al. Comparison of the instructional efficacy of internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA 2005;294:1043-51. (Pubitemid 41248445)
22. Khosravi A, Mehr GK, Kelishadi R, et al. The impact of a 6-year comprehensive community trial on the awareness, treatment and control rates of hyper tension in Iran: experiences from the Isfahan healthy heart program. BMC Cardiovasc Disord 2010;10:61.
23. Khosravi A, Shirani S, Shahrokhi S, Mohammadifard N, Ansari R. Antihypertensive drugs used by hypertensive patients in the provincial cities of Isfahan, Najafabad and Arak. ARYA Atherosclerosis J 2006;1:275-80.
24. Carella AM, Antonucci G, Conte M, Di Pumpo M, Gian-Cola A, Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Antonucci Curr Diabetes Rev 2010;6:215-21.
25. Rabiei K, Kelishadi R, Sarrafzadegan N, Sadri G, Amani A. Short-term results of community-based interventions for improving physical activity: Isfahan Healthy Heart Programme. Arch Med Sci 2010;6:32-9.
26. Tavassoli AA, Gharipour M, Siadat ZD, Bahonar A, Sadry GH. Are obesogenic behavioral, socioeconomic and metabolic determinants different in Iranian men and women? J Health Popul Nutr 2010;28:602-9.
27. Kanjilal S, Shanker J, Rao V, Mukherjee M, Iyengar SS, Kakkar V. Association of metabolic syndrome with atherothrombotic blood phenotypes in Asian Indian families with premature coronary artery disease. Arch Med Sci 2008;4:145-51.
28. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Ba-Nach M. Metabolic syndrome and renal disease. Int J Cardiol 2012 [Epub ahead of print].
29. Barylski M, Małyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011;7:1055-66.
30. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The rise and fall of hypertension: lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep 2011;5:174-9.